Pai Anant, El Shafei Maha M, Mohammed Osman A Z, Al Hashimi Mustafa
Ophthalmology Section, Surgery Department, Hamad Medical Corporation, Doha, Qatar.
Saudi J Ophthalmol. 2010 Oct;24(4):143-9. doi: 10.1016/j.sjopt.2010.06.003. Epub 2010 Jun 30.
Diabetic retinopathy (DR) is a major cause of preventable blindness in the developed countries. Despite the advances in understanding and management of DR, it remains a challenging condition to manage. The standard of care for patients with DR include strict metabolic control of hyperglycemia, blood pressure control, normalization of serum lipids, prompt retinal laser photocoagulation and vitrectomy. For patients who respond poorly and who progressively lose vision in spite of the standard of care, intravitreal administration of steroids or/and anti-vascular endothelial growth factor (anti-VEGF) drugs appear to be a promising second-line of therapy. This review discusses the current concepts and the role of these novel therapeutic approaches in the management of DR.
糖尿病视网膜病变（DR）是发达国家可预防失明的主要原因。尽管在DR的认识和管理方面取得了进展，但它仍然是一种具有挑战性的疾病。DR患者的护理标准包括严格代谢控制高血糖、控制血压、使血脂正常化、及时进行视网膜激光光凝和玻璃体切除术。对于反应不佳且尽管接受了标准治疗仍逐渐丧失视力的患者，玻璃体内注射类固醇或/和抗血管内皮生长因子（抗VEGF）药物似乎是一种有前景的二线治疗方法。本综述讨论了这些新型治疗方法在DR管理中的当前概念和作用。
